Aptamer’s Optimer Tech Powers Twist Bioscience’s New TrueAmp NGS Library Prep Kit

Aptamer Group Plc ( (GB:APTA) ) has shared an update.

Twist Bioscience has launched its new TrueAmp Library Preparation Kit for next-generation sequencing workflows, incorporating Aptamer Group’s proprietary Optimer binders to enable room-temperature stability and enhanced performance. The kit uses Twist’s in-house ligase and a newly developed TrueAmp polymerase, which is engineered to maximise coverage in difficult genomic regions while maintaining high accuracy.

The TrueAmp kit delivers high yields from low-input or degraded DNA samples, reducing amplification errors and improving data quality, and is validated with Twist’s HT-UDI and UMI adapter systems to support large-scale, multiplexed sequencing. The launch arises from Aptamer’s non-exclusive licensing agreement with Twist Bioscience for an Optimer inhibitor used in a high-fidelity polymerase, underscoring the commercial relevance of Aptamer’s technology and strengthening its position as an enabler in the expanding NGS market.

The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.84 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Spark’s Take on GB:APTA Stock

According to Spark, TipRanks’ AI Analyst, GB:APTA is a Neutral.

The score is held back primarily by very weak financial performance (sharp revenue decline, ongoing losses, and negative cash flows). Technicals are the main offset, showing a clear uptrend with supportive momentum. Valuation remains constrained by unprofitability and the absence of dividend information.

To see Spark’s full report on GB:APTA stock, click here.

More about Aptamer Group Plc

Aptamer Group plc is a life sciences company that develops next-generation synthetic binders, branded as Optimer, used as enabling reagents in research, diagnostics and therapeutic applications. The Group focuses on partnering with leading genomics and biotechnology players to integrate its Optimer technology into advanced workflows, particularly in the fast-growing next-generation sequencing market.

Average Trading Volume: 5,730,584

Technical Sentiment Signal: Buy

Current Market Cap: £24.95M

Learn more about APTA stock on TipRanks’ Stock Analysis page.